Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial.
continuous erythropoietin receptor activator
erythropoietin-stimulating agent
iron metabolism
japanese hemodialysis patients
renal anemia
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
16
12
2020
received:
20
11
2020
accepted:
22
12
2020
pubmed:
23
1
2021
medline:
29
6
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
Although continuous erythropoietin receptor activators (CERAs) are widely used erythropoiesis-stimulating agents for correcting renal anemia in patients undergoing hemodialysis (HD), few reports have examined weekly CERA administration. In this randomized controlled trial, we compared the efficacy and changes in the parameters of iron metabolism and erythropoiesis between weekly and biweekly CERA administration. In total, 120 patients undergoing maintenance HD were randomized to the weekly or biweekly group. The primary end point was the total CERA dose needed to maintain the target hemoglobin (Hb) levels during a 12-week evaluation period. There was no significant difference in the total dose between the weekly and biweekly groups (median 175.0 [interquartile range (IQR) 93.8-337.5] µg/12 weeks vs. 300.0 [IQR 125.0-375.0] µg/12 weeks, P = .18). The mean Hb levels during the evaluation period were 10.9 ± 0.8 g/dL in the weekly group and 10.7 ± 0.8 g/dL in the biweekly group (P = .25). Weekly CERA administration was well tolerated. Weekly CERA administration similarly managed anemia as biweekly administration in patients undergoing HD.
Identifiants
pubmed: 33481341
doi: 10.1111/jch.14171
pmc: PMC8678717
doi:
Substances chimiques
Hematinics
0
Hemoglobins
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
870-878Informations de copyright
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Références
J Clin Hypertens (Greenwich). 2021 Apr;23(4):870-878
pubmed: 33481341
Kidney Int. 1997 Jul;52(1):217-22
pubmed: 9211366
Nephrol Dial Transplant. 2004 May;19 Suppl 2:ii1-47
pubmed: 15206425
Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46
pubmed: 17699476
Blood. 2003 Aug 1;102(3):783-8
pubmed: 12663437
Blood Purif. 2014;38(3-4):174-9
pubmed: 25502179
Science. 2004 Dec 17;306(5704):2090-3
pubmed: 15514116
Clin J Am Soc Nephrol. 2006 Nov;1(6):1211-5
pubmed: 17699350
Kidney Int. 2004 May;65(5):1864-9
pubmed: 15086928
Lancet. 2007 Oct 20;370(9596):1415-21
pubmed: 17950856
J Biol Chem. 2001 Mar 16;276(11):7811-9
pubmed: 11113132
Am J Kidney Dis. 2004 Jul;44(1):94-111
pubmed: 15211443
Clin Chem Lab Med. 2005;43(11):1193-202
pubmed: 16232085
Ther Apher Dial. 2015 Apr;19(2):131-7
pubmed: 25257861
Blood. 2000 Aug 1;96(3):823-33
pubmed: 10910892
Ther Apher Dial. 2014 Oct;18(5):421-6
pubmed: 24456328
Ther Apher Dial. 2014 Oct;18(5):414-20
pubmed: 24456373
Ther Apher Dial. 2015 Apr;19(2):138-43
pubmed: 25402974
Rapid Commun Mass Spectrom. 2007;21(24):4033-8
pubmed: 18000836
J Am Soc Nephrol. 1997 Dec;8(12):1921-9
pubmed: 9402095
Lancet. 2006 Sep 9;368(9539):947-53
pubmed: 16962885